Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | HTR2A | P28223 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ASF1A | Q9Y294 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7523787 | 0.82 | LMNA (0.41) | ALDH1A1L3MBTL1MEN1KMT2AGAA | |
| SCHEMBL808442 | 0.77 | MEN1 (0.39) | ALDH1A1L3MBTL1MEN1KMT2AGAA | |
| SCHEMBL27661786 | 0.75 | MEN1 (0.38) | ALDH1A1L3MBTL1MEN1KMT2AGAA | |
| Bromide SCHEMBL28241411 | 0.75 | MEN1 (0.38) | ALDH1A1L3MBTL1MEN1KMT2AGAA | |
| SCHEMBL808497 | 0.73 | MEN1 (0.41) | ALDH1A1L3MBTL1MEN1KMT2AGAA | |
| SCHEMBL16161085 | 0.72 | L3MBTL1 (0.36) | ALDH1A1L3MBTL1MEN1KMT2AGAA | |
| SCHEMBL5029456 | 0.70 | ALDH1A1 (0.40) | ALDH1A1L3MBTL1GAATSHRLMNA | |
| SCHEMBL10665143 | 0.70 | HSP90AA1 (0.35) | ALDH1A1L3MBTL1MEN1KMT2AGAA | |
| SCHEMBL7096547 | 0.70 | ALDH1A1 (0.36) | ALDH1A1L3MBTL1MEN1KMT2AGAA | |
| SCHEMBL8190077 | 0.70 | GAA (0.41) | ALDH1A1MEN1KMT2AGAAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2789602-B1 | Omega-halo-2-alkynal, method for producing the same, and method for producing conjugated Z-alken-yn-yl acetate using the same | SHINETSU CHEMICAL CO (JP) | 2017-12-27 | — | — | EP | disclosed |
| US-9550720-B2 | Method for producing an ω-halo-2-alkynal | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2017-01-24 | — | — | US | disclosed |
| US-9376368-B2 | Method for producing a conjugated Z-alken-yn-yl acetate | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-06-28 | — | — | US | disclosed |
| CN-104098452-B | ω-halogen-2-alkynes aldehyde, produce its method and use it to produce the method for Z-chain Ene alkynyl base acetic acid esters of conjugation | SHIN-ETSU CHEMICAL INDUSTRY CO., LTD. (JP) | 2016-05-11 | — | — | CN | disclosed |
| US-20160107969-A1 | METHOD FOR PRODUCING AN OMEGA-HALO-2-ALKYNAL | SHINETSU CHEMICAL CO (JP) | 2016-04-21 | — | — | US | disclosed |
| US-20160107978-A1 | METHOD FOR PRODUCING A CONJUGATED Z-ALKEN-YN-YL ACETATE | SHINETSU CHEMICAL CO (JP) | 2016-04-21 | — | — | US | disclosed |
| US-9255056-B2 | Omega-halo-2-alkynal | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-02-09 | — | — | US | disclosed |
| US-20140309452-A1 | OMEGA-HALO-2-ALKYNAL, METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING CONJUGATED Z-ALKEN-YN-YL ACETATE USING SAME | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-10-16 | — | — | US | disclosed |
| EP-2789602-A1 | Omega-halo-2-alkynal, method for producing same, and method for producing conjugated Z-alken-yn-yl acetate using same | SHIN-ETSU CHEMICAL CO., LTD (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-20080171728-A1 | Efficient Process for Preparing Steroids and Vitamin D Derivatives With the Unnatural Configuration at C20 (20 Alpha-Methyl) from Pregnenolone | QUATRX PHARMACEUTICALS CO. | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309452-A1 | OMEGA-HALO-2-ALKYNAL, METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING CONJUGATED Z-ALKEN-YN-YL ACETATE USING SAME | NOTUM, SOAT2, FASN | ALDH1A1 641/4885L3MBTL1 2312/4885HTR2A 1555/4885 |
| US-20160107969-A1 | METHOD FOR PRODUCING AN OMEGA-HALO-2-ALKYNAL | HACL2, FASN, ALOX5 | ALDH1A1 754/4885L3MBTL1 1489/4885HTR2A 944/4885 |
| US-20080171728-A1 | Efficient Process for Preparing Steroids and Vitamin D Derivatives With the Unnatural Configuration at C20 (20 Alpha-Methyl) from Pregnenolone | CYP2R1, CYP24A1, VDR | ALDH1A1 1232/4885L3MBTL1 4685/4885HTR2A 3114/4885 |
| US-20160107978-A1 | METHOD FOR PRODUCING A CONJUGATED Z-ALKEN-YN-YL ACETATE | HACL2, FASN, ZYX | ALDH1A1 742/4885L3MBTL1 977/4885HTR2A 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.